Eli Lilly said on Friday that the European Medicines Agency (EMA) has recommended approval of its drug Kisunla for certain ...

IL-17 inhibitors are approved for axial spondyloarthritis and psoriatic arthritis, but their effectiveness in heavily ...

Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid ...

Eli Lilly and Company (NYSE:LLY) is experiencing a strong analyst sentiment amid its expanding role in cutting-edge ...

Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The company's oral ...

Eli Lilly (LLY) recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its Alzheimer's drug donanemab, underscoring the company's advancements in a ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Global pharmaceutical giants make billions of dollars in Australia but pay a fraction of that in tax. They say the price they ...

Eli Lilly's donanemab gets CHMP backing for early Alzheimer's in select patients after trials show reduced disease ...

Several anti-obesity drugs, including Ozempic, Wegovy and Mounjaro, have created buzz in the Indian markets. But are they really approved for use in India? What are their side-effects? And how much do ...

The popular weight-loss and diabetes drugs could play a significant role not only in disease prevention, but possibly in ...

Eli Lilly and Co. won the backing of European Union regulators for its Alzheimer’s disease drug Kisunla in a specific group ...